Guangzhou Pluslife Technology Co., Ltd.

Grantee website Guangzhou, GD, China
Purpose
To develop a next-generation molecular Point of Care Test (POCT) for detecting Rifampicin-resistant (RIF-resistant) TB to enable rapid diagnosis of drug-resistant TB, particularly in low-resource settings with high disease burden
Division
Global Health
Date
NOVEMBER 2024
Region served
AFRICA,
ASIA
Committed amount
$1,742,400
Grant topic
Enterics, Diagnostics, Genomics & Epidemiology,
Tuberculosis
Duration (months)
19
Grantee location
Guangzhou, GD, China

More about our work

Our story

Learn about the origins of the foundation and the values that drive our work.

Our work

Learn about where we work around the globe and the programs we’ve created to address urgent issues in global health, global development, and education.

How we work

We are focused on results. Those that can be measured. And those measured in ways beyond numbers.